NASDAQ:CFRX - ContraFect Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.87 +0.02 (+1.08 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$1.87
Today's Range$1.84 - $1.89
52-Week Range$0.80 - $2.31
Volume24,527 shs
Average Volume160,778 shs
Market Capitalization$132.65 million
P/E Ratio-5.05
Dividend YieldN/A
Beta-0.56

About ContraFect (NASDAQ:CFRX)

ContraFect logoContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Receive CFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CFRX
CUSIPN/A
Phone914-207-2300

Debt

Debt-to-Equity RatioN/A
Current Ratio10.63
Quick Ratio10.63

Price-To-Earnings

Trailing P/E Ratio-5.05
Forward P/E Ratio-5.19
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.17 per share
Price / Book11.00

Profitability

EPS (Most Recent Fiscal Year)($0.37)
Net Income$-15,510,000.00
Net MarginsN/A
Return on Equity-87.85%
Return on Assets-45.63%

Miscellaneous

Employees23
Outstanding Shares73,660,000

ContraFect (NASDAQ:CFRX) Frequently Asked Questions

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

How were ContraFect's earnings last quarter?

ContraFect (NASDAQ:CFRX) posted its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.09). View ContraFect's Earnings History.

When is ContraFect's next earnings date?

ContraFect is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for ContraFect.

Who are some of ContraFect's key competitors?

Who are ContraFect's key executives?

ContraFect's management team includes the folowing people:
  • Dr. Steven C. Gilman, Exec. Chairman, Chief Exec. Officer and Pres (Age 65)
  • Ms. Natalie Bogdanos J.D., Gen. Counsel and Corp. Sec. (Age 49)
  • Dr. Cara Cassino M.D., Chief Medical Officer and Exec. VP of R&D (Age 56)
  • Mr. Michael Messinger CPA, Sr. VP of Fin. (Age 43)
  • Ms. Nancy Dong, VP of Fin. & Admin. and Controller (Age 53)

Has ContraFect been receiving favorable news coverage?

News articles about CFRX stock have trended positive recently, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ContraFect earned a media sentiment score of 0.29 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 47.04 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are ContraFect's major shareholders?

ContraFect's stock is owned by many different of institutional and retail investors. Top institutional shareholders include DRW Securities LLC (0.15%), JPMorgan Chase & Co. (0.11%) and Opus Point Partners Management LLC (0.10%). Company insiders that own ContraFect stock include Cara M Cassino, Joshua B Muntner, Sol J Barer and Steven C Gilman. View Institutional Ownership Trends for ContraFect.

Which major investors are selling ContraFect stock?

CFRX stock was sold by a variety of institutional investors in the last quarter, including Opus Point Partners Management LLC. View Insider Buying and Selling for ContraFect.

Which major investors are buying ContraFect stock?

CFRX stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co. and DRW Securities LLC. Company insiders that have bought ContraFect stock in the last two years include Cara M Cassino, Joshua B Muntner, Sol J Barer and Steven C Gilman. View Insider Buying and Selling for ContraFect.

How do I buy shares of ContraFect?

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $1.87.

How big of a company is ContraFect?

ContraFect has a market capitalization of $132.65 million. The biotechnology company earns $-15,510,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 23 workers across the globe.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]


MarketBeat Community Rating for ContraFect (CFRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  195
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ContraFect (NASDAQ:CFRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for ContraFect in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

ContraFect (NASDAQ:CFRX) Consensus Price Target History

Price Target History for ContraFect (NASDAQ:CFRX)

ContraFect (NASDAQ:CFRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Maxim GroupReiterated RatingHoldLowView Rating Details
11/21/2016Piper Jaffray CompaniesSet Price TargetBuy$5.00N/AView Rating Details
9/28/2016William BlairInitiated CoverageOutperformN/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

ContraFect (NASDAQ:CFRX) Earnings History and Estimates Chart

Earnings by Quarter for ContraFect (NASDAQ:CFRX)

ContraFect (NASDAQ:CFRX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.39)
2019 EPS Consensus Estimate: ($0.35)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.09)($0.09)($0.09)
Q2 20181($0.10)($0.10)($0.10)
Q3 20181($0.10)($0.10)($0.10)
Q4 20181($0.10)($0.10)($0.10)
Q1 20191($0.08)($0.08)($0.08)
Q2 20191($0.09)($0.09)($0.09)
Q3 20191($0.09)($0.09)($0.09)
Q4 20191($0.09)($0.09)($0.09)

ContraFect (NASDAQ CFRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2018        
5/10/2018Q1 2018($0.09)($0.09)ViewN/AView Earnings Details
3/15/2018Q4 2017($0.0950)($0.06)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.11)$0.04ViewN/AView Earnings Details
8/9/2017Q2 2017($0.1830)($0.07)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.1670)($0.15)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.20)$0.01ViewN/AView Earnings Details
11/9/2016Q3 2016($0.21)($0.28)ViewN/AView Earnings Details
8/9/2016Q216($0.27)($0.35)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.25)($0.32)ViewN/AView Earnings Details
3/15/2016Q415($0.23)($0.28)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.29)($0.22)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.27)($0.33)ViewN/AView Earnings Details
5/15/2015Q1 2015($0.26)($0.24)ViewN/AView Earnings Details
4/6/2015Q4 2014($0.23)($0.23)ViewN/AView Earnings Details
11/14/2014Q3 2014($0.13)($1.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ContraFect (NASDAQ:CFRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ContraFect (NASDAQ CFRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.30%
Institutional Ownership Percentage: 59.16%
Insider Trading History for ContraFect (NASDAQ:CFRX)
Institutional Ownership by Quarter for ContraFect (NASDAQ:CFRX)

ContraFect (NASDAQ CFRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/25/2017Cara M CassinoInsiderBuy8,000$1.24$9,920.008,000View SEC Filing  
7/25/2017Joshua B MuntnerSVPBuy2,000$1.24$2,480.002,000View SEC Filing  
7/25/2017Sol J BarerDirectorBuy40,000$1.24$49,600.00815,933View SEC Filing  
7/25/2017Steven C GilmanCEOBuy800$1.24$992.0020,800View SEC Filing  
7/27/2016Steven C GilmanCEOBuy20,000$2.48$49,600.0020,000View SEC Filing  
11/17/2015Daniel CoutoSVPSell2,872$3.81$10,942.32View SEC Filing  
11/3/2015Daniel CoutoSVPSell2,867$4.23$12,127.412,872View SEC Filing  
10/20/2015Daniel CoutoSVPSell2,867$4.48$12,844.165,739View SEC Filing  
10/6/2015Daniel CoutoSVPSell2,867$4.11$11,783.378,606View SEC Filing  
9/22/2015Daniel CoutoSVPSell2,867$4.76$13,646.9210,773View SEC Filing  
9/8/2015Daniel CoutoSVPSell2,867$4.90$14,048.3014,340View SEC Filing  
3/2/2015Julia P GregoryCEOBuy11,778$4.61$54,296.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ContraFect (NASDAQ CFRX) News Headlines

Source:
DateHeadline
ContraFect (CFRX) to Post Q2 2018 Earnings of ($0.10) Per Share, Zacks Investment Research ForecastsContraFect (CFRX) to Post Q2 2018 Earnings of ($0.10) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - May 16 at 7:26 AM
CFRX: Multiple Presentations on CF-301 at ECCMIDCFRX: Multiple Presentations on CF-301 at ECCMID
finance.yahoo.com - May 14 at 4:27 PM
Analysts Offer Predictions for ContraFects FY2018 Earnings (CFRX)Analysts Offer Predictions for ContraFect's FY2018 Earnings (CFRX)
www.americanbankingnews.com - May 14 at 3:46 AM
ContraFect (CFRX) Announces  Earnings ResultsContraFect (CFRX) Announces Earnings Results
www.americanbankingnews.com - May 11 at 4:54 PM
BRIEF-ContraFect Announces Q1 Loss Per Share $0.26BRIEF-ContraFect Announces Q1 Loss Per Share $0.26
www.reuters.com - May 10 at 9:43 AM
ContraFect: 1Q Earnings SnapshotContraFect: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:43 AM
ContraFect Announces First Quarter 2018 Financial ResultsContraFect Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 9:43 AM
Zacks: Brokerages Expect ContraFect (CFRX) Will Announce Earnings of -$0.09 Per ShareZacks: Brokerages Expect ContraFect (CFRX) Will Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - May 9 at 3:10 AM
ValuEngine Upgrades ContraFect (CFRX) to SellValuEngine Upgrades ContraFect (CFRX) to Sell
www.americanbankingnews.com - May 3 at 10:19 PM
ContraFect (CFRX) to Release Quarterly Earnings on MondayContraFect (CFRX) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 9:57 AM
ContraFect (CFRX) Expected to Announce Earnings of -$0.09 Per ShareContraFect (CFRX) Expected to Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - April 21 at 11:14 PM
 Brokerages Anticipate ContraFect Corp (CFRX) to Post -$0.09 Earnings Per Share Brokerages Anticipate ContraFect Corp (CFRX) to Post -$0.09 Earnings Per Share
www.americanbankingnews.com - April 5 at 1:18 AM
Glancy Prongay & Murray LLP Announces Investigation on Behalf of ContraFect Corporation Investors (CFRX)Glancy Prongay & Murray LLP Announces Investigation on Behalf of ContraFect Corporation Investors (CFRX)
finance.yahoo.com - March 27 at 4:21 PM
Zacks Investment Research Weighs in on ContraFect Corps FY2018 Earnings (CFRX)Zacks Investment Research Weighs in on ContraFect Corp's FY2018 Earnings (CFRX)
www.americanbankingnews.com - March 23 at 10:54 AM
ContraFect Corp to Post Q1 2018 Earnings of ($0.09) Per Share, Zacks Investment Research Forecasts (CFRX)ContraFect Corp to Post Q1 2018 Earnings of ($0.09) Per Share, Zacks Investment Research Forecasts (CFRX)
www.americanbankingnews.com - March 22 at 9:06 AM
CFRX: No Safety Issues Noted Thus Far in Phase 2 Trial of CF-301CFRX: No Safety Issues Noted Thus Far in Phase 2 Trial of CF-301
finance.yahoo.com - March 21 at 4:22 PM
William Blair Comments on ContraFect Corps Q1 2019 Earnings (CFRX)William Blair Comments on ContraFect Corp's Q1 2019 Earnings (CFRX)
www.americanbankingnews.com - March 19 at 6:16 AM
 Brokerages Anticipate ContraFect Corp (CFRX) Will Announce Earnings of -$0.09 Per Share Brokerages Anticipate ContraFect Corp (CFRX) Will Announce Earnings of -$0.09 Per Share
www.americanbankingnews.com - March 18 at 11:08 PM
ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 15 at 9:26 AM
ContraFect reports 4Q lossContraFect reports 4Q loss
finance.yahoo.com - March 15 at 9:26 AM
ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK ConferenceContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference
finance.yahoo.com - March 14 at 10:33 AM
Broadfin Capital LLC Sells 1,479,895 Shares of ContraFect Corp (CFRX)Broadfin Capital LLC Sells 1,479,895 Shares of ContraFect Corp (CFRX)
www.americanbankingnews.com - March 3 at 4:55 AM
ContraFect Corp (CFRX) Expected to Post Earnings of -$0.10 Per ShareContraFect Corp (CFRX) Expected to Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - March 1 at 9:14 PM
Head-To-Head Review: ContraFect (CFRX) vs. VBI Vaccines (VBIV)Head-To-Head Review: ContraFect (CFRX) vs. VBI Vaccines (VBIV)
www.americanbankingnews.com - March 1 at 11:46 AM
Head to Head Comparison: ContraFect (CFRX) & SIGA Technologies (SIGA)Head to Head Comparison: ContraFect (CFRX) & SIGA Technologies (SIGA)
www.americanbankingnews.com - February 20 at 1:06 AM
Comparing VBI Vaccines (VBIV) & ContraFect (CFRX)Comparing VBI Vaccines (VBIV) & ContraFect (CFRX)
www.americanbankingnews.com - February 15 at 12:46 PM
-$0.10 Earnings Per Share Expected for ContraFect Corp (CFRX) This Quarter-$0.10 Earnings Per Share Expected for ContraFect Corp (CFRX) This Quarter
www.americanbankingnews.com - February 13 at 5:24 AM
Zacks: Analysts Expect ContraFect Corp (CFRX) Will Post Earnings of -$0.10 Per ShareZacks: Analysts Expect ContraFect Corp (CFRX) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - January 27 at 5:16 AM
Analyzing XOMA (XOMA) and ContraFect (CFRX)Analyzing XOMA (XOMA) and ContraFect (CFRX)
www.americanbankingnews.com - January 21 at 7:16 AM
ContraFect to Present at Cantor Antibiotics SummitContraFect to Present at Cantor Antibiotics Summit
finance.yahoo.com - January 11 at 10:20 AM
Head to Head Comparison: ContraFect (CFRX) & Mateon Therapeutics (MATN)Head to Head Comparison: ContraFect (CFRX) & Mateon Therapeutics (MATN)
www.americanbankingnews.com - January 7 at 9:40 PM
ContraFect to Present at 10th Annual Biotech ShowcaseContraFect to Present at 10th Annual Biotech Showcase
finance.yahoo.com - January 3 at 9:20 AM
 Brokerages Set $5.00 Target Price for ContraFect Corp (CFRX) Brokerages Set $5.00 Target Price for ContraFect Corp (CFRX)
www.americanbankingnews.com - December 30 at 1:46 PM
Comparing ContraFect (CFRX) & Mirati Therapeutics (MRTX)Comparing ContraFect (CFRX) & Mirati Therapeutics (MRTX)
www.americanbankingnews.com - December 28 at 3:02 PM
ContraFect (CFRX) vs. Soligenix (SNGX) Financial ComparisonContraFect (CFRX) vs. Soligenix (SNGX) Financial Comparison
www.americanbankingnews.com - December 24 at 9:33 PM
-$0.10 EPS Expected for ContraFect Corp (CFRX) This Quarter-$0.10 EPS Expected for ContraFect Corp (CFRX) This Quarter
www.americanbankingnews.com - December 24 at 5:32 PM
 Analysts Set $5.00 Price Target for ContraFect Corp (CFRX) Analysts Set $5.00 Price Target for ContraFect Corp (CFRX)
www.americanbankingnews.com - December 16 at 4:48 AM
Contrasting Jazz Pharmaceuticals (JAZZ) & ContraFect (CFRX)Contrasting Jazz Pharmaceuticals (JAZZ) & ContraFect (CFRX)
www.americanbankingnews.com - December 9 at 1:22 AM
 Brokerages Expect ContraFect Corporation (CFRX) Will Post Earnings of -$0.10 Per Share Brokerages Expect ContraFect Corporation (CFRX) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - December 7 at 1:20 AM
Zacks: Brokerages Set $5.00 Target Price for ContraFect Corporation (CFRX)Zacks: Brokerages Set $5.00 Target Price for ContraFect Corporation (CFRX)
www.americanbankingnews.com - November 30 at 2:18 PM
ContraFect Corporation (CFRX) Expected to Post FY2017 Earnings of ($0.33) Per ShareContraFect Corporation (CFRX) Expected to Post FY2017 Earnings of ($0.33) Per Share
www.americanbankingnews.com - November 30 at 7:32 AM
CFRX: Additional Data on CF-301 Presented at ID Week 2017CFRX: Additional Data on CF-301 Presented at ID Week 2017
finance.yahoo.com - November 27 at 6:19 PM
ContraFect (CFRX) and Windtree Therapeutics (WINT) Critical AnalysisContraFect (CFRX) and Windtree Therapeutics (WINT) Critical Analysis
www.americanbankingnews.com - November 25 at 7:12 PM
ContraFect to Present at the 29th Annual Piper Jaffray Healthcare ConferenceContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 16 at 12:39 PM
ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA ConferenceContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference
finance.yahoo.com - November 10 at 10:08 AM
ContraFect Announces Third Quarter 2017 Financial ResultsContraFect Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 7:58 PM
ContraFect reports 3Q lossContraFect reports 3Q loss
finance.yahoo.com - November 9 at 7:58 PM
Financial Analysis: ContraFect Corporation (CFRX) and Oncolytics Biotech, Inc. (USA) (ONCY)Financial Analysis: ContraFect Corporation (CFRX) and Oncolytics Biotech, Inc. (USA) (ONCY)
www.americanbankingnews.com - November 9 at 7:58 AM
Critical Comparison: ContraFect Corporation (CFRX) vs. Dendreon (DNDN)Critical Comparison: ContraFect Corporation (CFRX) vs. Dendreon (DNDN)
www.americanbankingnews.com - November 8 at 3:58 PM
Who Are The Major Shareholders Of ContraFect Corporation (CFRX)?Who Are The Major Shareholders Of ContraFect Corporation (CFRX)?
finance.yahoo.com - November 7 at 8:05 PM

SEC Filings

ContraFect (NASDAQ:CFRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ContraFect (NASDAQ:CFRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ContraFect (NASDAQ CFRX) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.